RDHL ▼ -2.2% - RedHill Biopharma Ltd. $RDHL - RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq® RedHill Biopharma declined 2.2% today despite announcing a transformational acquisition of commercialization rights to Ferring's Rebyota® and Clenpiq®, two marketed gastrointestinal products. The market's initial negative reaction to the deal suggests investor concerns about the acquisition terms, financing requirements, or integration risks that outweighed enthusiasm for expanding the company's commercial portfolio. 01-SEP-2026 07:02 AM ET